ArticleWorld journal of surgery2025
Survival Outcomes in Breast Cancer Patients With Metastatic Bone Disease.
Article in World journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics.Cancers · 2026Article
- Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers.Journal of cancer research and clinical oncology · 2026Article
- Survival Outcomes in Breast Cancer Patients With Metastatic Bone Disease.World journal of surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the survival outcomes of breast cancer patients with metastatic bone disease and to assess whether these patients exhibit different prognoses compared to those with more extensive metastatic involvement.
backgroundSystemic therapy including endocrine therapy, chemotherapy and targeted agents remains the cornerstone of treatment for patients with stage IV breast cancer, particularly those with bone metastases. Palliative radiotherapy also plays a key role in bone metastases, especially for symptom control and managing skeletal and complications. Although these modalities have significantly improved outcomes, the prognostic variation among patients with bone-only disease-ranging from solitary to widespread metastases-warrants further investigation. This study aims to evaluate survival outcomes among breast cancer patients with varying patterns of bone metastases.
methodsThis retrospective cohort study analyzed data from 4000 breast cancer patients treated between 2006 and 2024. Patients were evaluated for bone metastases, which were confirmed through imaging reviewed via the Picture Archiving and Communication System (PACS). Patients with confirmed bone metastases were categorized into solitary, oligometastatic (2-5 sites), or multiple metastases groups. Data on demographics, tumor characteristics, treatment regimens, surgery types, and survival outcomes were collected. Survival analyses were conducted using Kaplan-Meier curves and compared using log-rank tests.
resultsOne hundred and eighty-seven patients with metastatic bone disease were identified. 21 patients had solitary bone metastases only with a mean survival of 14.6 years. Additionally, 30 patients had oligometastatic bone disease only with a mean survival of 7 years. Another 31 patients had multiple bone only metastases, with also a mean survival of 7 years. Finally, 105 of the 187 patients had other metastases alongside bone metastases in other organs including the lung, liver, and brain with a mean survival of 6.3 years.
conclusionThese findings suggest that patients with bone-only metastases, particularly those with solitary lesions, exhibit significantly longer survival. Although systemic therapy remains the standard these findings suggest that patients with bone-only metastases, particularly those with solitary lesions, exhibit significantly longer survival. Although systemic therapy remains the standard, these findings highlight the need for further research into whether selected patients may benefit from integrating local treatment approaches, including surgery, into their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.